Practice Guidelines Regarding Psychologists’ Involvement in Pharmacological Issues

CITATION
(2011, October 17). Practice Guidelines Regarding Psychologists’ Involvement in
Pharmacological Issues. American Psychologist. Advance online publication. doi:
10.1037/a0025890

These guidelines were developed by the American Psychological Association (APA) Division 55 (American Society for the Advancement of Pharmacotherapy) Task Force on Practice Guidelines. The task force was chaired by Robert E. McGrath. Task force members included Stanley Berman, Elaine LeVine, Elaine Mantell, Beth Rom–Rymer, Morgan Sammons, and James Quillin. Additional input on the guidelines was provided by Robert Ax, representing Division 18 (Psychologists in Public Service). None of the individuals involved in the development of this document has any personal investment in pharmaceutical products of any kind, nor did the developers receive any financial support for its creation.

The task force anticipates that these guidelines may deserve reconsideration in a relatively brief time frame, given anticipated changes in psychologists’ role in pharmacotherapy as well as changes in the perceptions and use of psychotropic medications. In particular, it is the belief of the members of the task force that future efforts should include consideration of whether some elements of the enclosed guidelines merit elevation to the level of practice standards. Accordingly, this document is scheduled to expire as APA policy in August 2014, five years after the date of its approval and adoption by the APA Council of Representatives. After this date, users are encouraged to contact the APA Practice Directorate to confirm whether this document remains in effect.

Correspondence concerning this article should be addressed to the Practice Directorate, American Psychological Association, 750 First Street, NE, Washington, DC 20002–4242.

Downloads:

More Practice Guidelines Regarding Psychologists' Involvement in Pharmacological Issues